Evercore ISI raises Repligen price target to $160
Evercore ISI Group analyst Daniel Markowitz maintained an Outperform rating on Repligen (NASDAQ: RGEN) and raised the price target to $160 from $150.
*this image is generated using AI for illustrative purposes only.
Evercore ISI Group analyst Daniel Markowitz has maintained an Outperform rating on Repligen (NASDAQ: RGEN) while raising the price target. The new target stands at $160, an increase from the previous $150.
Rating and Target Details
The adjustment reflects a positive outlook on the stock. The following table summarizes the revised ratings:
| Metric | Value |
|---|---|
| Rating | Outperform |
| Previous Price Target | $150 |
| New Price Target | $160 |
What specific factors drove Evercore ISI to raise the price target for Repligen?
How might this rating change influence investor sentiment toward Repligen in the short term?
What upcoming catalysts could further impact Repligen's stock performance?
15
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
